Last reviewed · How we verify
Urokinase-Derived Peptide A6 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Urokinase-Derived Peptide A6 (Urokinase-Derived Peptide A6) — Gynecologic Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Urokinase-Derived Peptide A6 TARGET | Urokinase-Derived Peptide A6 | Gynecologic Oncology Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Urokinase-Derived Peptide A6 CI watch — RSS
- Urokinase-Derived Peptide A6 CI watch — Atom
- Urokinase-Derived Peptide A6 CI watch — JSON
- Urokinase-Derived Peptide A6 alone — RSS
Cite this brief
Drug Landscape (2026). Urokinase-Derived Peptide A6 — Competitive Intelligence Brief. https://druglandscape.com/ci/urokinase-derived-peptide-a6. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab